In a study on intraperitoneal metastasis of ovarian cancer, researchers found that deletion of Tissue transglutaminase (TG2), an enzyme overexpressed in primary ovarian cancer, can delay intraperitoneal metastasis of ovarian cancer and reduce ascites. Here, TGM2 is linked to ovarian cancer.